Engineers Gate Manager LP Takes $1.48 Million Position in Enliven Therapeutics, Inc. $ELVN

Engineers Gate Manager LP acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the second quarter, HoldingsChannel.com reports. The fund acquired 29,152 shares of the company’s stock, valued at approximately $1,479,000.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Enliven Therapeutics in the second quarter valued at $221,255,000. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Enliven Therapeutics by 3.5% during the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock worth $32,399,000 after buying an additional 28,095 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth about $30,617,000. Finally, Siren L.L.C. bought a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $29,252,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Buying and Selling at Enliven Therapeutics

In other news, Director Mika Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 180,831 shares of company stock worth $10,735,269 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

ELVN has been the topic of several analyst reports. The Goldman Sachs Group upped their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Barclays started coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price target for the company. William Blair began coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating on the stock. HC Wainwright increased their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Finally, Stifel Nicolaus increased their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $49.12 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $62.32. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -29.41 and a beta of 0.30. The firm’s 50-day moving average is $56.50 and its 200-day moving average is $45.89.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.